Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago

Core Insights - Co-Diagnostics, Inc. is participating in the ADLM annual meeting and expo from July 28 to August 1, 2024, in Chicago, IL, showcasing its advancements in molecular diagnostics [1][2]. Company Overview - Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostic technologies, focusing on nucleic acid detection and analysis [4]. Product Development - The company is introducing its new at-home and point-of-care Co-Dx™ PCR platform aimed at addressing the global diagnostics gap, with a focus on various indications including tuberculosis (TB) [2][6]. - The first FDA 510(k) application for a COVID-19 test was submitted in mid-June, with additional tests in the pipeline to cater to a diverse global market [2][3]. Presentation and Engagement - A special company presentation will be held on July 30, featuring CEO Dwight Egan and Executive VP Joseph Featherstone, discussing the company's role in the global initiative to end TB by 2030 [6]. - The Co-Dx booth will also showcase the Co-Dx PCR Pro™ instrument, which is currently under FDA review and not available for sale [3][7].